The End of Alzheimer’s: The Brain and Beyond

— —

Thomas J. Lewis (RealHealth Clinics, USA) Clement L. Trempe (Clinical Assistant in Ophthalmology, Harvard Medical School, Boston, MA, USA; Assistant in Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA)

The End of Alzheimer’s

The Brain and Beyond

Thomas J. Lewis (RealHealth Clinics, USA), Clement L. Trempe (Clinical Assistant in Ophthalmology, Harvard Medical School, Boston, MA, USA; Assistant in Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA)

$101.95

Paperback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Academic Press Inc
12 May 2017

Psychology of ageing; Geriatric medicine; Neurosciences

The End of Alzheimer’s: The Brain and Beyond, Second Edition is the first comprehensive overview on the molecular basis of Alzheimer’s outside of the brain, merging the most recent findings within the field into a single book. It aims to educate the reader on the many overlooked aspects of Alzheimer’s disease that occur outside the brain.

This book uniquely provides step-by-step, peer-reviewed evidence that the current research model may be misguided and that a new and emerging model is more accurate. It carefully outlines the molecular research in Alzheimer’s outside the brain and argues that a more thorough, whole-body diagnosis will provide better answers about its causes and lead to new treatments.

It is beneficial to researchers who need to be apprised of the emerging science on the causes of Alzheimer’s, and will hopefully redirect many into new avenues of cellular research and discovery.

By: Thomas J. Lewis (RealHealth Clinics USA), Clement L. Trempe (Clinical Assistant in Ophthalmology, Harvard Medical School, Boston, MA, USA; Assistant in Ophthalmology, Massachusetts Eye and Ear Infirmary, Boston, MA, USA)
Imprint: Academic Press Inc
Country of Publication: United States
Edition: 2nd edition
Dimensions: Height: 234mm, Width: 191mm,
Weight: 950g
ISBN: 9780128121122
ISBN 10: 0128121122
Pages: 482
Publication Date: 12 May 2017
Audience: Professional and scholarly , Undergraduate
Format: Paperback
Publisher's Status: Active

"1. Is it Alzheimer’s?2. The Amyloid Cascade Hypothesis3. Diagnosis of Alzheimer’s4. Molecular Causes and Research5. Can Medicine Save You?6. A New Diagnostic Paradigm – The Molecular Eye7. Inflammation – Friend or Foe?8. Alzheimer’s Beyond the Brain – Molecular Research in the Body9. Does Infection Cause Alzheimer’s?10. Alzheimer’s Disease Prevention 11. Differential Diagnosis toward a Cure for Alzheimer’s Appendix1: Signs, symptoms, and stages of Alzheimer’s2: Alzheimer’s Research at the Cellular Level3: Concept of a Medical ""Cure""4: Alzheimer’s Disease Statistics5: Eye and Whole Body Diseases"

"Dr. Lewis is an inorganic and physical chemist with degrees from Worcester Polytechnic Institute (WPI) and the Massachusetts Institute of Technology (MIT). In addition to a Ph.D., Dr. Lewis has training from the Harvard School of Public Health in Toxicology, Industrial Hygiene, and a certificate in Industrial Hygiene from the University of Massachusetts. Fundamentally Dr. Lewis is a medical researcher and medical information translator. Much of his knowledge comes for the clinical work of Dr. Clement L. Trempe and Dr. Kilmer McCully. These clinicians are pioneers in systemic chronic diseases, disease detection using ocular biomarkers, germ theory, inflammatory diseases, and micronutrient balance in immune health. He is the founder of the RealHealth companies including RealHealth Clinics. Dr. Lewis is also engaged in developing new small molecule therapeutics for the treatment of diseases of aging, with special focus on Alzheimer’s disease. Dr. Lewis holds patents (pending) on novel approaches to treat cancer and methods and approaches for treating chronic diseases of aging, including Alzheimer’s disease and macular degeneration. In addition, he has patents pending on a new risk calculator for chronic disease which he has trademarked ""chronic disease temperature(tm)."" Dr. Trempe received his MD degree from Ottawa Medical School, Canada. He furthered his studies at Harvard’s Schepens Eye Research Institute (SERI) and Massachusetts Eye and Ear Infirmary, Boston. He has been on staff at Harvard Medical School teaching hospitals since the 1970s. Dr. Trempe didn’t set out to solve the Alzheimer’s conundrum, he instead set out to treat eye diseases in a different way: treat the causes of the sick body and the health of the eye will also improve. When Dr. Trempe started diagnosing and treating his “eye patients for systemic diseases, their eyes got better and stayed much better compared to people who were treated as if their eyes existed in isolation from the rest of the body. This multidisciplinary approach resulted in many patients with serious disease beyond the eye reporting that their other conditions improved upon Dr. Trempe’s “eye (whole body) treatments. One of those conditions that improved was Alzheimer’s disease. His medical career at Harvard Medical School has spanned five decades. He is the author of hundreds of medical/scientific papers, two pending patents, and two books."